BMC Cancer最新文献

{"title":"ACOXL-AS1's pan-cancer dynamics and its proliferative impact on endometrial endometrioid carcinoma.","authors":"Hongrong Wu, Ruilin Lin, Liangli Hong","doi":"10.1186/s12885-025-15005-y","DOIUrl":"https://doi.org/10.1186/s12885-025-15005-y","url":null,"abstract":"<p><strong>Background: </strong>Long non-coding RNAs (lncRNAs) are critically involved in carcinogenesis; however, the pan-cancer significance and functional mechanisms of ACOXL-AS1 remain largely uncharacterized. This study comprehensively investigates the expression landscape, prognostic value, and biological impact of ACOXL-AS1 across multiple malignancies, with a specific focus on its pro-proliferative role in endometrial endometrioid carcinoma (EEC).</p><p><strong>Methods: </strong>We analyzed ACOXL-AS1 expression and its association with clinical outcomes using pan-cancer RNA-seq data from TCGA and GTEx databases. Functional validation was performed in EEC cell lines (HHUA, HEC-1 A) via lentivirus-mediated overexpression, followed by CCK-8, colony formation, and transwell migration/invasion assays. Mechanistic insights were investigated using integrated bioinformatics approaches.</p><p><strong>Results: </strong>ACOXL-AS1 was significantly downregulated in most cancers, and higher expression correlated with improved prognosis. Elevated ACOXL-AS1 levels were associated with smaller tumor size, lower disease stage, reduced metastasis, and decreased tumor mutational burden (TMB)/microsatellite instability (MSI). It also modulated the immunosuppressive tumor microenvironment. Critically, ACOXL-AS1 overexpression significantly inhibited EEC cell proliferation, migration, invasion, and tumor growth in xenograft models. Mechanistically, it may regulate RPA4 expression through the homologous recombination pathway in EEC cells.</p><p><strong>Conclusions: </strong>ACOXL-AS1 may play a role as a tumor suppressor in endometrial endometrioid carcinoma (EEC), suggesting its potential as a prognostic biomarker and a candidate for further exploration as a therapeutic target.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1522"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs.","authors":"Mohammed Rafea Kanaan, Jessica Schmitz, Jan Hinrich Braesen, Markus Antonius Kuczyk, Hossein Tezval","doi":"10.1186/s12885-025-15042-7","DOIUrl":"https://doi.org/10.1186/s12885-025-15042-7","url":null,"abstract":"<p><p>Upper tract urothelial carcinoma (UTUC) and urinary bladder cancer (UBC), though histologically similar, differ molecularly, prompting interest in their biomarker profiles for targeted therapies like antibody-drug conjugates (ADCs) enfortumab vedotin (targeting Nectin-4) and sacituzumab govitecan (targeting TROP-2). This study investigated Nectin-4 and TROP-2 expression in 87 UTUC patients, including 54 with a history of concurrent UBC (UTUC + UBC) and 33 with UTUC alone. Immunohistochemical analysis revealed widespread TROP-2 expression (98.8% of samples), with high levels linked to low-grade UTUC (p = 0.043) and intense staining (mean H-score 227 ± 63) across both cohorts. Nectin-4 was expressed in 70.1% of samples overall but was more frequent in the UTUC + UBC group (88.8% vs. 63.6% in UTUC-only patients), though this difference lacked statistical significance (p = 0.340). Notably, Nectin-4 staining intensity was weak in both groups (mean H-score 66 ± 65), suggesting biological distinctions between UTUC with and without UBC. The findings imply that ADCs targeting TROP-2 and Nectin-4 may hold therapeutic promise in UTUC without requiring prior biomarker testing. Additionally, the elevated Nectin-4 expression in UTUC + UBC patients hints at divergent molecular pathways that could influence treatment strategies, warranting further clinical exploration.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1525"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting hematologic toxicity in advanced cervical cancer patients using interpretable machine learning models based on radiomics and dosimetrics.","authors":"Jun Zhu, Qionghui Zhou, Luqiao Chen, Zhipeng He, Jianfeng Tan, Jinmeng Pang, Qianxi Ni","doi":"10.1186/s12885-025-14999-9","DOIUrl":"https://doi.org/10.1186/s12885-025-14999-9","url":null,"abstract":"<p><strong>Background and objectives: </strong>Hematologic toxicity (HT) is a common and serious side effect for advanced cervical cancer patients undergoing chemoradiotherapy. Accurately predicting HT can significantly improve patient management and treatment outcomes. This study aims to develop and evaluate interpretable machine learning models that use radiomic and dosimetric features to predict HT in advanced cervical cancer patients.</p><p><strong>Methods and materials: </strong>Retrospectively collected general clinical data, planning CT images, and dose files from 205 patients with advanced cervical cancer who underwent chemoradiotherapy, and classified them according to the severity of HT. Radiomics and dosiomics features were extracted from the same region of interest, and feature selection was performed using a random forest algorithm. Radiomics models, dosiomics models, and hybrid models were then constructed based on extreme gradient boosting trees. Sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC) were calculated to evaluate the classification performance of the models. Finally, SHAP values were used to perform interpretability analysis on the best model to enhance the transparency and practicality of the model.</p><p><strong>Results: </strong>The sensitivity, specificity, and AUC values for the radiomics model were 0.42, 0.86, and 0.78, respectively, while those for the dosiomics model were 0.50, 0.90, and 0.74. In contrast, the hybrid model exhibited superior classification performance with sensitivity, specificity, and AUC values of 0.50, 0.83, and 0.83, respectively. Compared to the standalone radiomics and dosiomics models, the hybrid model demonstrated enhanced classification capability. Interpretability analysis based on SHAP values not only provided a ranking of feature importance and the distribution of feature impacts on model outputs but also elucidated the specific decision-making processes influenced by these features and the interactions between them. This enables clinicians to gain a more intuitive understanding of the model's decisions.</p><p><strong>Conclusions: </strong>For patients with advanced cervical cancer undergoing chemoradiotherapy, the integration of radiomics and dosiomics features can significantly enhance the classification performance of predictive models, thereby holding considerable potential for refining patient treatment strategies. Interpretability analysis based on SHAP values can aid clinicians in more readily understanding the model's decisions, thus promoting the effective implementation of the model in clinical practice.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1516"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vismodegib treatment in locally advanced basal cell carcinoma limited to the facial region: a single-center experience.","authors":"İvo Gökmen, Erdem Şen","doi":"10.1186/s12885-025-14914-2","DOIUrl":"https://doi.org/10.1186/s12885-025-14914-2","url":null,"abstract":"<p><strong>Introduction: </strong>Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. Treatment typically begins with surgical intervention. However, in cases of locally advanced and metastatic BCC (laBCC and mBCC), Hedgehog signaling pathway inhibitors such as sonidegib and vismodegib are used.</p><p><strong>Materials and methods: </strong>This retrospective study included 28 adult patients with laBCC who were treated with 150 mg daily oral vismodegib at Mehmet Akif Ersoy State Hospital between 2018 and 2023. Patients were monitored until disease progression, intolerable side effects, or treatment discontinuation. Treatment efficacy was evaluated using objective response rate (ORR) and disease control rate (DCR). Safety was assessed based on adverse events (AEs) reported in accordance with the CTCAE v. 5.0 classification. Statistical analyses, including overall survival (OS) and progression-free survival (PFS), were performed and analyzed using SPSS version 25.</p><p><strong>Results: </strong>The overall ORR was 89.3%, with 39.3% of patients achieving complete response (CR). The median PFS was 15.1 months, and the median OS was 37.5 months. Female gender and prior surgical interventions were identified as independent prognostic factors for PFS, while ECOG-PS score and the duration of vismodegib exposure were significant predictors of OS. AEs were reported in 78.6% of patients, with dysgeusia and muscle spasms being the most prevalent. Grade 3 or 4 toxicity occurred in 14.5% of patients, and 13% (n = 3) discontinued treatment due to AEs. Patients receiving treatment for ≥ 12 months experienced a higher incidence of AEs (92.9%) compared to those treated for < 12 months (64.3%).</p><p><strong>Conclusion: </strong>Vismodegib demonstrated high efficacy in treating patients with laBCC, with a significant proportion achieving CR. However, long-term treatment was associated with an increased incidence of AEs, highlighting the need for careful monitoring of safety in prolonged therapies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1514"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer.","authors":"Koji Takada, Shinichiro Kashiwagi, Mariko Nishikawa, Asuka Kochi, Chika Watanabe, Haruhito Kinoshita, Kana Ogisawa, Masatsune Shibutani, Tamami Morisaki","doi":"10.1186/s12885-025-14970-8","DOIUrl":"https://doi.org/10.1186/s12885-025-14970-8","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1518"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High sodium intake: a silent killer driving global gastric cancer burden.","authors":"Xiqiang Zhang, Zhaoyi Jing, Ao Yu, Xinzhen Xu, Hua Meng, Kexin Wang","doi":"10.1186/s12885-025-14891-6","DOIUrl":"https://doi.org/10.1186/s12885-025-14891-6","url":null,"abstract":"<p><strong>Background: </strong>High sodium intake is a recognized risk factor for increased gastric cancer mortality. This study examines the trends and distribution of stomach cancer burden associated with high sodium intake from 1990 to 2021, with a focus on its relationship with age, period, and birth cohort.</p><p><strong>Methods: </strong>Utilizing data from the 2021 Global Burden of Disease study, we applied an age-period-cohort model to conduct statistical analysis. We calculated age, period, and cohort effects, as well as net drift (overall annual percentage change), for gastric cancer deaths and disability-adjusted life years (DALYs) associated with high sodium intake across 204 countries and regions.</p><p><strong>Results: </strong>In 2021, 7.93% of global gastric cancer deaths and 7.92% of DALYs were linked to high sodium intake. Populations in East Asia and those with a high-middle Sociodemographic Index (SDI) bore the heaviest burden. Over the 32-year period, the global age-standardized mortality rate [Net drift = -2.33(95%CI:-2.37 to -2.28)] and age-standardized DALYs rate [Net drift = -2.56(95%CI:-2.65 to -2.47)] generally demonstrated a declining trend, particularly in high SDI regions [Net drift =-2.91 (95%CI: -3.02 to -2.81)]. China, as a representative country, exhibited unfavorable age, period, and cohort effects. Future projections suggest further declines in mortality and DALYs numbers, along with corresponding age-standardized rates.</p><p><strong>Conclusion: </strong>Despite ongoing global efforts to reduce sodium intake, gastric cancer remains a significant public health challenge, especially in East Asia. The findings underscore the necessity of developing targeted prevention strategies for high-risk groups, such as the elderly and males, to mitigate the global burden of gastric cancer.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1517"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High FGFR4 protein expression, but not FGFR1 or FGFR2, predicts poor prognosis in pancreatic ductal adenocarcinoma.","authors":"Marcin Braun, Justyna Durślewicz, Julia Sołek, Zuzanna Nowicka, Aleksandra Zielińska, Paulina Antosik, Dariusz Grzanka","doi":"10.1186/s12885-025-14976-2","DOIUrl":"https://doi.org/10.1186/s12885-025-14976-2","url":null,"abstract":"<p><strong>Background: </strong>The number of prognostic and predictive factors for pancreatic ductal adenocarcinoma (PDAC) is limited. Fibroblast growth factor receptors (FGFRs) are emerging as potential therapeutic targets, especially in cases with FGFR2 gene fusions. However, the prognostic relevance of FGFR1, FGFR2, and FGFR4 protein expression in PDAC remains unclear.</p><p><strong>Methods: </strong>Immunohistochemical analysis of FGFR1, FGFR2, and FGFR4 was performed on 99 PDAC and 60 adjacent normal pancreatic tissue samples. Protein expression was quantified using the H-score method and correlated with clinicopathological variables and survival. Publicly available datasets from the GEO repository and the cancer genome atlas (TCGA) were used for pathway enrichment analysis and validation of findings at the mRNA level.</p><p><strong>Results: </strong>FGFR2 and FGFR4 showed differential expression between tumor and normal tissues, while FGFR1 did not. High FGFR4 protein expression was significantly associated with shorter disease-free survival (DFS) in both univariable and multivariable analyses. FGFR2 high expression cases showed a trend towards poor DFS, while FGFR1 had no prognostic impact. In silico analysis confirmed that high FGFR4 mRNA levels are associated with worse DFS. Co-expression and enrichment analysis linked FGFR4 overexpression with developmental, metabolic, and stemness-related processes.</p><p><strong>Conclusion: </strong>FGFR4 showed the strongest prognostic association among the FGFR family members studied, with high protein expression correlating with shorter disease-free survival in PDAC patients. These findings underscore the potential of FGFR4 as a biomarker for recurrence risk, while also highlighting the complexity of FGFR-related signaling and its context-dependent clinical relevance.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1519"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of systemic inflammatory markers on EGFR-mutant non-small cell lung cancer.","authors":"Supagone Wangsubtawee, Thanaporn Thamrongjirapat, Narumol Trachu, Pimpin Incharoen, Natini Jinawath, Passaworn Cheyasawan, Nanamon Monnamo, Dittapol Munthum, Nattanan Reungwetwattana, Salin Amponnavarat, Pimtip Sanvarinda, Arthit Chairoungdua, Montien Ngodngamtaweesuk, Khantong Khiewngam, Ekaphop Sirachainan, Phichai Chansriwong, Thitiya Dejthevaporn, Thanyanan Reungwetwattana, Putthapoom Lumjiaktase","doi":"10.1186/s12885-025-14915-1","DOIUrl":"10.1186/s12885-025-14915-1","url":null,"abstract":"<p><strong>Background: </strong>High prevalence of EGFRm lung cancer was found in the Asian population. Preclinical data suggest that inflammatory cytokines activated by PM2.5 affected EGFRm clone expansion. Here, we explored the correlation between inflammatory markers and EGFRm NSCLC.</p><p><strong>Methods: </strong>Resected NSCLC patients (2016-2023) were enrolled. Tumor tissues and blood serum were retrieved from Ramathibodi tumor biobank. EGFR 19del and L858R mutations were performed by rt-PCR in cancerous tissue and dPCR in normal tissue in the same patient. NF-Kb and STAT3 protein signaling were measured by ELISA in both cancerous and normal tissue. Cytokines (IL-1ß, IL-6, IL-8, IL-10, IL-12 and TNF-α) were explored in serum by flow cytometry.</p><p><strong>Results: </strong>Among 140 patients, EGFRm prevalence was 58% in cancerous tissue but only 5% in normal tissue. NF-kB and STAT3 were statistically higher in cancerous tissue than normal tissue [NF-kB median O.D.=0.82 (IQR; 0.07-2.82) vs. 0.32 (IQR; 0.05-2.48), P < 0.001; STAT3 median O.D.=0.32 (IQR; 0.10-1.58) vs. 0.17 (IQR; 0.06-1.29, P < 0.001]. STAT3 was significantly increased in EGFRm compared to EGFRwt [median O.D.=0.36 (IQR; 0.234-0.592) vs. 0.23 (IQR; 0.158-0.409), OR = 11.09 (95% CI; 2.17-56.58), P = 0.004]. TNF-α, IL-10, and STAT3 in cancer cells were higher in EGFRm than EGFRwt (P = 0.003, 0.008, and < 0.001, respectively). None of cytokines was statistically different between EGFRm and EGFRwt patients. However, only STAT3 in cancer cells and non-smoker were associated with EGFRm NSCLC in multivariable analysis.</p><p><strong>Conclusion: </strong>Inflammation could be one of the pathogenesis of both NSCLC and EGFRm lung cancer as we demonstrated in our pilot study. STAT3 is a potentially inflammatory-predictive biomarkers. Larger cohort is needed.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1510"},"PeriodicalIF":3.4,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variations in radiomic features of the femoral head and neck during helical tomotherapy in prostate and rectal cancer patients.","authors":"Maryam Gholizade, Elmira Yazdani, Fatemeh Sadat Hosseini-Baharanchi, Alireza Nikoofar, Golbarg Esmaili, Foad Goli-Ahmadabad, Seied Rabi Mahdavi, Malakeh Malekzadeh","doi":"10.1186/s12885-025-14903-5","DOIUrl":"10.1186/s12885-025-14903-5","url":null,"abstract":"<p><strong>Background: </strong>This study introduces a novel approach for screening bone alterations in the femoral head and neck (H&N) of prostate cancer (PCa) and rectal cancer (RCa) patients during helical tomotherapy (HT) using megavoltage computed tomography (MVCT) images. The goal is to identify robust radiomic features (RFs) with the highest percentage changes during treatment and examine their correlation with the administered dose.</p><p><strong>Methods: </strong>Reproducible RFs were identified through a test-retest analysis using a cheese phantom. This study involved 20 male patients (10 PCa, 10 RCa). The left and right femoral H&N regions were segmented on MVCT images from the initial, middle, and final HT sessions. Absolute RF values and relative percentage changes were analyzed using repeated measures analysis of variance (ANOVA). The Pearson correlation coefficient with Benjamini-Hochberg adjustment (q < 0.05) was used to evaluate the relationship between altered RFs and the dose (Gy).</p><p><strong>Results: </strong>The femoral H&N had the highest relative percentage changes (RPCs) for intensity-histogram (IH) and intensity-based (IB) RFs, respectively, with texture-based RFs providing insights into radiotherapy-induced changes. Strong correlations (r ~ -0.7) were observed between changes in H&N RFs and dose (Gy) in PCa. For RCa, IB features, including the IB_Coefficient_of_Variation (r = 0.54) for the neck, and IH RFs, such as IH_Minimum_Histogram_Gradient (r = -0.51) and IB_Robust_Mean_Absolute_Deviation (r = 0.55) for the head, showed significant correlations.</p><p><strong>Conclusions: </strong>Among robust RFs, the most highly correlated with dose alterations were IB, IH, and gray-level co-occurrence matrix (GLCM)-based RFs. The RFs at mid- and end-treatment varied with dose fractionation. Percentage changes in robust MVCT features during HT may serve as early markers.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1509"},"PeriodicalIF":3.4,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"α-L-fucosidase isoenzymes (FUCA1/FUCA2) as prognostic markers in gliomas: a comprehensive study.","authors":"Chao Zuo, Yi Liu, Ziqiang Wang, Hailian Chen, Yu Wang, Yongchao Qiao","doi":"10.1186/s12885-025-15049-0","DOIUrl":"10.1186/s12885-025-15049-0","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1511"},"PeriodicalIF":3.4,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}